Media stories about Edwards Lifesciences Corporation (NYSE:EW) have trended somewhat positive recently, Accern reports. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Edwards Lifesciences Corporation earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave news coverage about the medical research company an impact score of 46.8681530047098 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the media stories that may have effected Accern Sentiment’s scoring:

Edwards Lifesciences Corporation (NYSE:EW) traded up $1.39 on Tuesday, reaching $105.24. 1,104,700 shares of the company traded hands, compared to its average volume of 1,647,799. The company has a market capitalization of $22,110.00, a price-to-earnings ratio of 28.77, a P/E/G ratio of 1.86 and a beta of 0.46. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.76 and a current ratio of 3.49. Edwards Lifesciences Corporation has a one year low of $81.12 and a one year high of $121.45.

Edwards Lifesciences Corporation (NYSE:EW) last posted its quarterly earnings results on Tuesday, October 24th. The medical research company reported $0.84 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.86 by ($0.02). The company had revenue of $821.50 million for the quarter, compared to the consensus estimate of $833.85 million. Edwards Lifesciences Corporation had a net margin of 22.47% and a return on equity of 27.22%. Edwards Lifesciences Corporation’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.68 EPS. equities analysts predict that Edwards Lifesciences Corporation will post 3.75 EPS for the current year.

A number of research firms recently issued reports on EW. BMO Capital Markets reiterated a “buy” rating and set a $132.00 target price on shares of Edwards Lifesciences Corporation in a research report on Friday, September 1st. William Blair reiterated an “outperform” rating on shares of Edwards Lifesciences Corporation in a research report on Monday, August 28th. Barclays PLC boosted their target price on shares of Edwards Lifesciences Corporation from $108.00 to $120.00 and gave the company an “equal weight” rating in a research report on Thursday, July 27th. Zacks Investment Research upgraded shares of Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $130.00 target price on the stock in a research report on Tuesday, July 18th. Finally, Royal Bank Of Canada reiterated a “buy” rating and set a $130.00 target price on shares of Edwards Lifesciences Corporation in a research report on Friday, September 1st. Seven analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. Edwards Lifesciences Corporation has an average rating of “Buy” and a consensus price target of $125.17.

TRADEMARK VIOLATION WARNING: This piece of content was first published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-edwards-lifesciences-corporation-ew-stock-price/1702576.html.

In other Edwards Lifesciences Corporation news, Director Schack Wesley W. Von sold 1,000 shares of the company’s stock in a transaction dated Thursday, November 9th. The shares were sold at an average price of $104.15, for a total transaction of $104,150.00. Following the sale, the director now directly owns 2,622 shares of the company’s stock, valued at $273,081.30. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Michael A. Mussallem sold 32,900 shares of the company’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $112.45, for a total transaction of $3,699,605.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 139,580 shares of company stock valued at $15,143,994. 2.13% of the stock is owned by company insiders.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.